Clinical Trials Logo
  1. Home
  2. Corona Virus Infection
  3. NCT04682574
  4. Details
NCT04682574 Clinical Trial

Role of Mega Dose of Vitamin C in Critical COVID-19 Patients

Corona Virus Infection Clinical Trial

Official title:
Effects of Mega Dose Vitamin C in Critically Ill COVID-19 Patients: A Randomized Control Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04682574
Other study ID # IRBEC/BIH/09-2020
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2, 2020
Est. completion date March 10, 2022

Study information
Verified date May 2022
Source University of Lahore
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Vitamin C (ascorbic acid) is a water-soluble vitamin having anti-inflammatory, immunomodulatory, anti-oxidative, antithrombotic and antiviral properties. Considering these effects vitamin C should have beneficial impact in patients suffering from sepsis and acute respiratory distress syndrome (ARDS). The current study is designed to assess the beneficial effects of Vitamin C in COVID-19 infected patients.

Recruitment information / eligibility
Status Completed
Enrollment 278
Est. completion date March 10, 2022
Est. primary completion date February 28, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: critically ill patients admitted in ICU Exclusion Criteria: allergic to Vitamin C didnt given the consent

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Vitamin C
mega dose is given to the selected critically ill patients

Locations
Country Name City State
Pakistan Bahria Town International Hospital Lahore Punjab

Sponsors (1)
Lead Sponsor Collaborator
University of Lahore

Country where clinical trial is conducted

Pakistan, 

Outcome
Type Measure Description Time frame Safety issue
Primary Partial pressure of Oxygen in arterial blood to fraction of inspired Oxygen (P/F ratio) 1 and 4th day
Primary Survival analysis 28 days follow up
Secondary Length of Hospital stay Admission to discharge
Secondary Need for intubation number of intubations needed in both groups. 28 days
Secondary Inflammatory markers comparison of the inflammatory markers, CRP, D.Dimer, Procalcitonin, LDH, TLC and hematological variables at day four after the intervention started. before the start of treatment (day 1) and on day 4
Secondary APACHE II score before the start of treatment (day 1) and on day 4
See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04578210 - Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia Phase 1/Phase 2
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Completed NCT04720794 - A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion N/A
Enrolling by invitation NCT04659486 - Adolescents With COVID-19/MIS-C at HCFMUSP N/A
Completed NCT04598620 - Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate
Completed NCT05517941 - Effect of Active Cycle Breathing Technique Along With Incentive Spirometer on COVID19 Patient N/A
Recruiting NCT04565782 - Corona Virus Infection Among Liver Transplant Recipients
Recruiting NCT04480333 - Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 Phase 1
Active, not recruiting NCT04558476 - Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation Phase 2
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Completed NCT05639998 - BBV152/BBV154 Heterologus Prime-Boost Study Phase 2
Completed NCT05736926 - Anal Fissure Among Survivors of COVID-19 Virus Infection.
Completed NCT04523246 - Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents Early Phase 1
Withdrawn NCT04386447 - Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 Phase 2
Recruiting NCT04583566 - Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04579588 - Understanding Immunity to the Flu Vaccine in COVID-19 Patients
Terminated NCT03331445 - Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections Phase 2
Recruiting NCT04573348 - T Cells Response to SARS COV 2 Peptides